Mucopolysaccharidosis Type 3 B: Clinical Trials

2 trials for Mucopolysaccharidosis Type 3 B, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Terminated 1
Phase 21Terminated 1

Follow Mucopolysaccharidosis Type 3 B: new trials by email Literature Review of Mucopolysaccharidosis Type 3 B trials Research Report on Mucopolysaccharidosis Type 3 B

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB
rAAV9.CMV.hNAGLU - Mucopolysaccharidosis Type 3 B
Phase 1 / Phase 2TerminatedAbeona Therapeutics, Inc112017-10-162022-05-05
A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
Mucopolysaccharidosis Type IIIB, Mucopolysaccharidosis Type 3 B
CompletedAllievex Corporation222015-11-012020-03-06

Narrower conditions

Mucopolysaccharidosis III (2)

Broader conditions

Carbohydrate Metabolism, Inborn Errors (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Connective Tissue Diseases (2)  ·  Genetic Diseases, Inborn (2)  ·  Lysosomal Storage Diseases (2)  ·  Metabolic Diseases (2)  ·  Metabolism, Inborn Errors (2)  ·  Mucinoses (2)  ·  Mucopolysaccharidoses (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Skin and Connective Tissue Diseases (2)

Sponsors

Abeona Therapeutics, Inc (1)  ·  Allievex Corporation (1)

Countries

Germany (2)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  Colombia (1)  ·  France (1)  ·  Taiwan (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Results publications

PMID 32884151, PMID 35709957